# Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

> **NCT00004857** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 86 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00004857
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2003-03
- **Final completion:** 2010-02
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004857, "Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00004857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*